MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fnut.2026.1818450

Медицинская библиотека · Frontiers in nutrition · 2026

Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.

Russo Cristina, Valle Maria Stella, Surdo Sofia, Tuttobene Michele, Cambria Maria Teresa, Malaguarnera Lucia

СтатьяСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

Sarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function. Vitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance. Whether this mechanistic rationale has translated into phenotype-defined randomized clinical trials remains unclear.

METHODS

We conducted a systematic dual-track search across PubMed, Scopus, and Web of Science to identify randomized controlled trials (RCTs) evaluating isolated vitamin D or resveratrol supplementation in adults with explicitly defined sarcopenic obesity or meeting implicit SO phenotype criteria, defined as the concurrent presence of adiposity and objective muscle impairment at baseline. Trials lacking confirmation of both components at enrollment were excluded. Risk of bias was assessed using Cochrane RoB 2.0.

RESULTS

The search retrieved five records (PubMed n = 5; Scopus n = 0; Web of Science n = 0). Following full-text assessment, none met eligibility criteria requiring baseline confirmation of both adiposity and sarcopenia together with isolated vitamin D or resveratrol supplementation (n = 0). Retrieved RCTs in related populations did not simultaneously require adiposity and muscle impairment as enrollment criteria. As a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified.

CONCLUSION

Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking. Future RCTs must adopt phenotype-defined enrollment strategies integrating adiposity, muscle dysfunction, and mechanistic endpoints to determine whether micronutrient signaling can meaningfully modify outcomes in SO.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261307248, identifier PROSPERO (CRD420261307248).

Для цитирования: Russo Cristina, Valle Maria Stella, Surdo Sofia, Tuttobene Michele, Cambria Maria Teresa, Malaguarnera Lucia. Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.. Frontiers in nutrition. 2026. DOI: 10.3389/fnut.2026.1818450.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.